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Case Presentation
A 66-year-old Caucasian female recently diagnosed with mixed 
connective tissue disease presented with acute onset vision loss 
in the left eye. The patient first noted a “hazy-shower” that 
caused blurry vision with loss of peripheral vision. Her vision 
progressively worsened over a four-day period, resulting in 
complete blindness in the left eye and the onset of blurry vision 
in her right eye. She denied any eye pain, discharge, photophobia 
or similar symptoms in the past. The patient did note a very 
mild headache for four days but denied any other symptoms. 
Investigations
The patient was admitted for workup of left eye vision loss. 
Rheumatology was consulted for concern of autoimmune 
vasculitis, and the patient was started on IV methylprednisolone 
(1g daily). There was a concern for giant cell arteritis (GCA). 
Therefore bilateral temporal artery biopsies were obtained. 
The biopsy specimens showed no signs of GCA; however some 
ophthalmic artery occlusion was noted. There was concern for 
further thromboses, so MRI, MRA, and MRV of the head, CT 
of the chest, abdomen and pelvis, ultrasound of the carotid 
arteries, and trans-esophageal echocardiogram were performed. 
However, all of these imaging studies were non-diagnostic.
The patient had an Orbital Duplex Scan that showed 
significantly reduced blood flow to both eyes. Laboratory 
testing for autoimmune markers were significant for a positive 
rheumatoid factor (RF) and positive anti-cyclic citrullinated 
protein (anti-CCP) antibody (Ab). An ANA screen was positive 
with a titer of 1:80. Anti-ssDNA and anti-dsDNA antibodies 
were both moderately elevated. All other studies were 
non-diagnostic including anti-Smith Ab, RNP Ab, anti-SS-A 
Ab, anti-SS-B Ab, C-reactive protein, erythrocyte sedimentation 
rate, cryoglobulins, C-ANCA, P-ANCA.
Differential Diagnosis
Vasculitides are defined by the presence of inflammatory 
leukocytes in vessel walls with reactive damage to mural 
structures and may occur as a primary process or secondary to 
another underlying disease.1 There was initial concern for GCA 
due to the age of onset, presence of headaches, and absence of 
other symptoms. However, the bilateral temporal artery biopsies 
were negative. Essential cryoglobulinemic vasculitis was also 
considered; however it was ruled out based on the absence of 
serum cryoglobulins. 
Given the patient’s past medical history and positive ANA, 
the medical team suspected an underlying connective tissue 
disorder. Additionally, due to the absence of serum ANCAs, 
the differential diagnosis was narrowed to a non-ANCA 
vasculitides. An important differential to bear in mind is 
systemic lupus erythematosus (SLE), a chronic, autoimmune 
connective tissue disorder affecting multiple organ systems 
often with a relapsing and remitting clinical course. Ocular 
manifestations, occurring in up to one third of patients, result 
from localized ischemia.2,3 Lupus retinopathy is one of the most 
common vision-threatening complications of SLE, occurring in 
up to 29% of patients.6-8 
Another etiology to consider is rheumatoid arthritis (RA). Blood 
vessel inflammation is a central feature of RA.9 The mean onset 
of vasculitic symptoms is 13.6 years after the initial diagnosis 
of RA, and patients typically have developed rheumatoid 
nodules.10,11 The two principal ocular manifestations of 
rheumatoid vasculitis are episcleritis and peripheral ulcerative 
keratitis.12,13 The presence of an elevated RF and positive ANA, 
as well as a past medical history of nodular episcleritis, led to a 
high clinical suspicion for rheumatoid vasculitis.
Treatment
Rheumatology and Ophthalmology agreed to continue the IV 
methylprednisolone. On hospital day four, the patient was given 
cyclophosphamide (750 mg/m2) to be dosed monthly. This 
decision was based primarily on two critical studies investigating 
the efficacy and safety of pulse IV cyclophosphamide.
In mildly progressive ocular inflammation, therapy is often 
initiated with immunomodulatory agents prior to pulse IV 
cyclophosphamide. However, with failed immunomodulatory 
therapy or rapidly progressing inflammation at presentation, 
initiation of pulse IV cyclophosphamide is warranted. In 2004, 
Durrani et al. demonstrated the control of inflammation and 
steroid-sparing effect of pulse IV cyclophosphamide in 38 
patients with severe ocular inflammation of diverse etiologies.14 
Cyclophosphamide is a non-specific alkylating agent that exerts 
a cytotoxic effect on rapidly proliferating cells. It has shown 
remarkable safety in the rheumatologic and dermatologic 
literature when used IV for limited periods.15,16 
Outcome and Follow-up
The patient continued on methylprednisolone (1g daily) for 
a total of eight days. On hospital day nine, her daily dose of 
methylprednisolone was decreased to 250 mg. At this time, 
her vision was stable in the right eye; however she still had 
complete loss of vision and light perception in her left eye. On 
hospital day ten, her steroid dose was adjusted to prednisone 
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(100 mg daily), which she would continue until her next dose 
of cyclophosphamide. The patient had a repeat Orbital Duplex 
scan on hospital day ten which showed stable parameters in 
the central retinal artery of the right eye and improved flow in 
the temporal vessel of the short posterior ciliary system in the 
left eye. On hospital day 11, the patient was medically stable 
for discharge with close follow up with Ophthalmology, Retina 
Clinic, and Rheumatology.
Discussion
The initial differential diagnosis of sudden-onset vision loss 
includes infectious etiologies, primary ocular disorders, 
systemic vasculitides, connective tissue diseases, malignancy, 
and idiopathic processes. This patient’s past medical history 
and clinical presentation were most consistent with a vasculitis 
secondary to an underlying connective tissue disease. Ultimately, 
the patient had symptoms suggestive of several different 
connective tissue diseases and was discharged with a diagnosis 
of non-ANCA autoimmune vasculitis.
Key Points
Patients presenting with sudden onset vision loss suspected 
to be due to vasculitis warrant urgent diagnostic work-up to 
confirm the diagnosis. Although making a final diagnosis is a 
challenge due to the non-specific nature of clinical symptoms 
and lack of precise diagnostic modalities, early identification of 
vision loss secondary to an underlying connective tissue disease 
is critical in guiding management and maintaining visual acuity. 
Early initiation of steroids is the mainstay in preventing further 
vision loss while maintaining stability with immunomodulating 
drugs is an emerging treatment modality. 
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